Pharmaceutical manufacturers of Insulin glargine

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

Founded in 1978, Biocon Limited is the largest biotechnology company in India and a leading company in Asia, focusing on biopharmaceuticals and research services. It is an integrated and innovation-driven enterprise that provides affordable solutions for chronic diseases globally. The company develops, manufactures, and offers a diverse portfolio of Small Molecules APIs & Formulations and Complex Biologics, including Novels and Biosimilars like MAbs, rh-insulin& Insulin Analogs. Among its notable products are the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG, and India's first biologic BioMAb-EGFR for head and neck cancer. Additionally, it has developed Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, introduced as Alzumab for psoriasis in India in 2013.

Established in 1998, Gan & Lee Pharmaceuticals is an advanced biopharmaceutical company specialized in the exploration, formulation, manufacturing, and marketing of insulin and its derivatives, holding a prominent position in the diabetes sector in China. Since its establishment, Gan & Lee has directed its efforts toward insulin synthesis. In 1998, Gan & Lee achieved a significant milestone by creating the initial domestically produced biosynthetic human insulin, a development acknowledged as one of China's top 10 scientific and technological advancements by the Chinese Academy of Sciences and Engineering. Up to now, Gan & Lee has introduced several comparable biosimilar insulin derivative products.

Kalbe has come a long way since its humble beginnings in a garage to emerge as the primary pharmaceutical company in Indonesia. Through both natural growth and mergers & acquisitions, Kalbe has broadened its business interests and evolved into a provider of comprehensive healthcare solutions through its four business divisions: the Prescription Pharmaceutical Division (23% contribution), Consumer Health Division (17% contribution), Nutritionals Division (30% contribution), and Distribution and Logistics Division (30% contribution).

Tonghua Dongbao Group Import & Export Co.,Ltd. (Formerly known as Dongbao Group Imp & Exp Co.,Ltd.; Tonghua Dongbao Imp &Exp Co., Ltd.) was founded in 1993 and is a wholly owned subsidiary of Dongbao Group. Serving as the primary entity for Dongbao Group's international operations, it functions as the central administrative unit for the group's overseas economic and trade activities.

Nanjing Cuccess Pharmaceutical operates as a division of Nanjing Hanxin Pharmaceutical, a subsidiary of AMPHASTAR Group, a publicly traded company in the United States. Our focus lies in the development and production of biopharmaceuticals, encompassing recombinant drugs such as Peptides (e.g., Semaglutide, Liraglutide), Enzymes (e.g., CPB, KEX II Protease, Enterokinase, Trypsin), as well as ingredients for personal care and cosmetics (e.g., PDRN, Ergothioneine, Hyaluronic Acid, Humaniz...).